Clinical Trial Update: Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations [Phase 1]

View source ↗

Summary

Phase I clinical trials are evaluating Axitinib for potential efficacy in patients with BRCA1/2 mutations, including breast and ovarian cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Lynkcell Europe | Conditions: Breast Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED